clinical trial · NCT05844228
A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218
Renal ImpairmentVIR-2218
brief summary
The rationale of this study is to evaluate the impact of renal function on the PK, safety, and tolerability of VIR-2218 in participants with normal renal function and participants with varying degrees of renal dysfunction who are otherwise medically stable
started
Jun 1, 2023
primary completion
Mar 1, 2025
completion
Apr 21, 2025
last updated
Oct 16, 2026
detailed description
Participants may be enrolled in Cohorts 1 and 2 in a non-randomized way.
official title
A Phase 1, Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of VIR-2218 in Adult Participants With Renal Impairment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol